Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review

References

• Reference annotations:
   Google Scholar
• Of interest:
   Google Scholar
• *Brandes A, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22(23):4779–4786.
   Google Scholar
• *Vredenburgh J, Desjardins A, Herndon J, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–4729.
   Google Scholar
• Of particular interest:
   Google Scholar
• **Friedman H, Prados M, Wen P, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
   Google Scholar
• Tsang DS, Khan L, Perry JR, et al.. Survival Outcomes in Elderly Patients with Glioblastoma. Clin Oncol. 2015;27(3):176–183.
   Web of Science ®Google Scholar
• Thakkar P, Dolecek A, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985–1996.
   PubMed Web of Science ®Google Scholar
• Hilmani S, Barakat A, Kamar A, et al. Prognostic factors of survival in Moroccan patients with Glioblastoma. Journal of Solid Tumors. 2014;4(1):42.
   Google Scholar
• Thumma S, Fairbanks R, Lamoreaux W, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012;10(1):75.
   PubMed Web of Science ®Google Scholar
• Kaur G, Bloch O, Jian B, et al. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival: Clinical article. J Neurosurg. 2011;115(4):754–759.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason W, Van Den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Atkins R, Ng W, Stylli S, et al. Repair mechanisms help glioblastoma resist treatment. J Clin Neurosci. 2015;22(1):14–20.
   PubMed Web of Science ®Google Scholar
• Stupp R, Van Den Bent MJ, Erridge SC, et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). J Clin Oncol. 2010;28:15s (suppl; abstr TPS152).
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu P, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142–148.
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Eriksen J, Broholm H, et al. Prospective evaluation of angiogenic, hypoxic and EGFR‐related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. Apmis. 2010;118(8):585–594.
   PubMed Web of Science ®Google Scholar
• Peereboom D, Ahluwalia M, Ye X, et al. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology. 2013;15(4):490–496.
   PubMed Web of Science ®Google Scholar
• Ahluwalia M. Society for Neuro-Oncology Annual Meeting: a report of selected studies. Expert Rev Anticancer Ther. 2011;11(2):161–163.
   Google Scholar
• Pommier Y, Leo E, Zhang H, et al.. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010;17:421–433.
   PubMed Web of Science ®Google Scholar
• De Jong FA, Van Der Bol JM, Mathijssen RH, et al. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther. 2007;6(9):1364–1370.
   Google Scholar
• Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29(12):5171–5184.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62(10):1006–1012.
   PubMed Web of Science ®Google Scholar
• Brandes A, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Journal of Clinical Oncology. 2004;22(23):4779–4786.
   PubMed Web of Science ®Google Scholar
• Vredenburgh J, Desjardins A, Herndon J, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–4729.
   PubMed Web of Science ®Google Scholar
• Friedman H, Prados M, Wen P, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
   PubMed Web of Science ®Google Scholar
• Reardon D, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. 2012;107(1):155–164.
   PubMed Web of Science ®Google Scholar
• Reardon D, Desjardins A, Peters K, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011;117(23):5351–5358.
   PubMed Web of Science ®Google Scholar
• Reardon D, Quinn J, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005;103(2):329–338.
   PubMed Web of Science ®Google Scholar
• Fadul C, Kingman L, Meyer L, et al. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol. 2008;90(2):229–235.
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010;12(5):508–516.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–745.
   PubMed Web of Science ®Google Scholar
• Prados M, Lamborn K, Yung W, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology. 2006;8(2):189–193.
   PubMed Web of Science ®Google Scholar
• Puduvalli V, Giglio P, Groves M, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-oncology. 2008;10(2):216–222.
   PubMed Web of Science ®Google Scholar
• Møller S, Grunnet K, Hansen S, et al. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol (Madr). 2012;51(6):797–804.
   PubMed Web of Science ®Google Scholar
• Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors. Cancer. 2008;112(10):2267–2273.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol (Meeting Abstracts). 2009;27(15S):2011.
   Google Scholar
• Reardon D, Vredenburgh J, Coan A, et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011;105(3):621–627.
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Chowdhary S, Potthast L, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol. 2012;14(1):93–100.
   PubMed Web of Science ®Google Scholar
• Reynés G, Balañá C, Gallego O, et al. A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. Anticancer Drugs. 2014;25(6):717–722.
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329–336.
   PubMed Web of Science ®Google Scholar
• Gil M, De Las Penas R, Reynes G, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs. 2012;23(6):659–665.
   PubMed Web of Science ®Google Scholar
• Ruiz-Sánchez D, Alaguero Calero M, Sastre-Heres A, et al. Effectiveness of the bevacizumab- irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second- line treatments without this regimen. Oncology Letters. 2012;4(5):1114–1118.
   PubMed Web of Science ®Google Scholar
• Raval S, Hwang S, Dorsett L. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). ASCO Annu Meet Proc. 2007;25(18_suppl):2078.
   Google Scholar
• Iruarrizaga E, Azkona E, Aresti U, et al. Bevacizumab (BV) plus irinotecan (I) in recurrent glioblastoma multiforme (GBM): A single center experience. J Clin Oncol. 2013;31:(suppl; abstr e13000).
   Google Scholar
• Stankewitz S, Dresemann G. Addition of continuous low dose temozolomide (T) to bevacizumab (Bev) plus irinotecan (Iri) after bevacizumab plus irinotecan failure in heavily pretreated glioblastoma multiforme (GBM). ASCO Annu Meet Proc. 2009;27(15S):e13015.
   Google Scholar
• Grude F, Campone M, Frenel J, et al. Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): Results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire. J Clin Oncol. 2011;29. (suppl; abstr 2086).
   Google Scholar
• Dresemann A, Hobbold A, Dresemann G Bevacizumab (B) plus irinotecan (I) in progressive multiple pretreated andtemozolomide (T) refractory glioblastoma multiforme (GBM): A single center experience using a low dose regimen. In: ASCO meeting abstracts. Vol 26, No 15S (May 20 Supplement), 2008;13007.
   Google Scholar
• Demirci U, Tufan G, Aktas B, et al. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Cancer Res Clin Oncol. 2013;139(5):829–835.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Reardon DA, et al. Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma. Cancer. 2009;115(13):2964–2970.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48(1):52–58.
   PubMed Web of Science ®Google Scholar
• Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008;109(2):268–272.
   Google Scholar
• Kang TY, Jin T, Elinzano H, et al.. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008;89(1):113–118.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004;6(1):21–27.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17(5):1516.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Filka E, Nelson G, et al. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol. 2002;25(2):204–208.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Expert Rev Anticancer Ther. 2015;15(1):129–141.
   PubMed Web of Science ®Google Scholar
• Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol. 2004;27(1):33–38.
   PubMed Web of Science ®Google Scholar
• Goldwirt L, Beccaria K, Carpentier A, et al. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. J Neurooncol. 2015;122(2):273–281.
   PubMed Web of Science ®Google Scholar
• Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci. 2012;19(12):1636–1640.
   PubMed Web of Science ®Google Scholar
• Khasraw M, Ameratunga M, Grant R, et al. Antiangiogenic therapy for high‐grade glioma. Cochrane Database Syst Rev. 2014;22(9):CD008218.
   Google Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol. 2014;92(3):194–207.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev Anticancer Ther. 2015;15(1):129–141.
   PubMed Web of Science ®Google Scholar